Article
Oncology
Fu-Jia Liu, Wen-Yan Cheng, Xiao-Jing Lin, Shi-Yang Wang, Tian-Yi Jiang, Ting-Ting Ma, Yong-Mei Zhu, Yang Shen
Summary: This study demonstrated that the combination of MFC MRD and molecular MRD can establish prognostic value in AML patients with specific genetic lesions. After two cycles of consolidation, MFC MRD showed independent predictive significance for clinical outcomes, highlighting the importance of integrating different MRD assessment methods based on genetic characteristics of AML.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Thomas Cluzeau, Roberto M. Lemoli, James McCloskey, Todd Cooper
Summary: Assessment of measurable residual disease (MRD) is important in predicting outcomes and managing high-risk acute myeloid leukemia (AML). However, there is currently no consensus on the best method for determining MRD negativity, making comparisons across studies difficult.
Editorial Material
Oncology
Tali Azenkot, Brian A. Jonas
Summary: Measurable residual disease (MRD) has become a primary marker of risk severity and prognosis in acute myeloid leukemia (AML). However, there is ongoing debate about the monitoring and treatment based on MRD. The identified literature has described the prognostic value of pre-transplant MRD and suggested optimal timing and techniques to quantify MRD. Several studies have addressed the implications of MRD on treatment selection and hematopoietic stem cell transplant, but more prospective, randomized studies are needed to guide the application of MRD in AML treatment, particularly in transplantation.
Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Maximilian A. Roehnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christian Thiede, Stefan W. Krause, Veit Buecklein, Joerg Hoffmann, Sonia Jaramillo, Richard F. Schlenk, Christoph Roellig, Martin Bornhaeuser, Nicholas McCarthy, Sylvie Freeman, Uta Oelschlaegel, Malte von Bonin
Summary: Measurable residual disease (MRD) detected by MFC is associated with unfavorable outcome in AML patients. A simple and standardized eight-color panel with fixed gates allows for rapid and accurate detection of MRD. This strategy provides prognostic information and identifies independent risk factors in AML patients.
Article
Oncology
Shin Yeu Ong, Melinda Tan Si Yun, Nurul Aidah Abdul Halim, Dheepa Christopher, Wei Ying Jen, Christian Gallardo, Angeline Tan Hwee Yim, Yeow Kheong Woon, Heng Joo Ng, Melissa Ooi, Gee Chuan Wong
Summary: Flow cytometry can detect measurable residual disease in acute myeloid leukemia patients and is valuable for assessing treatment efficacy and predicting prognosis. This study found that detectable residual disease after less intensive chemotherapy was associated with a higher risk of relapse, shorter progression-free survival, and overall survival.
Review
Oncology
Roland B. Walter, Yishai Ofran, Agnieszka Wierzbowska, Farhad Ravandi, Christopher S. Hourigan, Lok Lam Ngai, Adriano Venditti, Francesco Buccisano, Gert J. Ossenkoppele, Gail J. Roboz
Summary: MRD testing in AML is an important biomarker for predicting patient outcomes and early detection of relapse. However, there are still open questions regarding the optimal timing and frequency of testing, as well as defining thresholds for relapse. Studies confirming the direct impact of treatment effects on MRD to clinical outcomes are needed to establish MRD as a surrogate endpoint in AML.
Article
Oncology
Jong-Mi Lee, Silvia Park, Insik Hwang, Dain Kang, Byung Sik Cho, Hee-Je Kim, Ari Ahn, Myungshin Kim, Yonggoo Kim
Summary: This article presents an ITD-tracing algorithm based on NGS method for monitoring MRD in AML patients. The assay shows high sensitivity and superior performance, and demonstrates prognostic value in AML patients undergoing allogeneic hematopoietic stem cell transplantation.
Review
Biochemistry & Molecular Biology
Ing S. Tiong, Sun Loo
Summary: Measurable residual disease (MRD) assessment plays an important role in prognostication and guiding treatment decisions in acute myeloid leukemia (AML). With the development of new therapeutics and the recent approval of NPM1 MRD as a regulatory endpoint, MRD-directed therapy and its potential application in clinical trials are being explored. This article reviews emerging molecular MRD markers, the impact of novel therapeutics on MRD endpoints, and the use of MRD as a predictive biomarker in guiding therapy in AML.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Selina M. Luger
Summary: The Oncology Grand Rounds series aims to provide readers with a better understanding of applying key study results to their clinical practice through case presentations and literature reviews.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Hematology
Anne-Sofie Skou, Kristian Lovvik Juul-Dam, Hans B. Ommen, Henrik Hasle
Summary: Longitudinal molecular measurable residual disease (MRD) sampling post-therapy completion is an effective tool for identifying imminent relapse of AML among patients in long-term hematological complete remission. Superiority of peripheral blood MRD assessment in distinguishing disease states and potential for preemptive intervention in AML relapse are highlighted.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Joshua A. Fein, Roni Shouval, Jacques-Emmanuel Galimard, Myriam Labopin, Gerard Socie, Juergen Finke, Jan J. Cornelissen, Ram Malladi, Maija Itala-Remes, Patrice Chevallier, Kim H. Orchard, Donald Bunjes, Mahmoud Aljurf, Marie Therese Rubio, Jurjen Versluis, Mohamad Mohty, Arnon Nagler
Summary: Older age and comorbidities are factors that influence the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. This study aimed to determine the impact of individual comorbidities and their cumulative burden on the risk of nonrelapse mortality (NRM) in patients receiving low-intensity regimens. The findings showed an association between cardiac comorbidity, psychiatric disease, and increased NRM risk.
Review
Oncology
Mamoon Ahmed, Daniel A. Pollyea
Summary: Acute myeloid leukemia is an aggressive hematological malignancy that requires the development of lower intensity therapies for elderly and comorbid patients.
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Eduardo Ramos Elbal, Jose Luis Fuster, Jose Antonio Campillo, Ana Maria Galera, Mar Bermudez Cortes, Maria Esther Llinares, Irene Jimenez, Mercedes Plaza, Helios Martinez Banaclocha, Jose Antonio Galian, Miguel Blanquer Blanquer, Maria Victoria Martinez Sanchez, Manuel Muro, Alfredo Minguela
Summary: In this study, three MRD monitoring methods (MFC, FISH, and PCR) were used to anticipate relapse of childhood AML. However, preemptive therapies were not effective in preventing disease progression. Therefore, more sensitive MRD monitoring methods and more effective preemptive therapies are needed.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Letter
Hematology
Shirleny R. Cardoso, Alicia C. M. Ellison, Amanda J. Walne, David Cassiman, Manoj Raghavan, Bhuvan Kishore, Philip Ancliff, Carmen Rodriguez-Vigil, Bieke Dobbels, Ana Rio-Machin, Ahad F. H. Al Seraihi, Nikolas Pontikos, Hemanth Tummala, Tom Vulliamy, Inderjeet Dokal
Article
Cell Biology
Justin Loke, Salam A. Assi, Maria Rosaria Imperato, Anetta Ptasinska, Pierre Cauchy, Yura Grabovska, Natalia Martinez Soria, Manoj Raghavan, H. Ruud Delwel, Peter N. Cockerill, Olaf Heidenreich, Constanze Bonifer
Letter
Hematology
Shirleny R. Cardoso, Alicia C. M. Ellison, Amanda J. Walne, David Cassiman, Manoj Raghavan, Bhuvan Kishore, Philip Ancliff, Carmen Rodriguez-Vigil, Bieke Dobbels, Ana Rio-Machin, Ahad F. H. Al Seraihi, Nikolas Pontikos, Hemanth Tummala, Tom Vulliamy, Inderjeet Dokal
Article
Oncology
Rachel Bayley, Daniel Blakemore, Laila Cancian, Stephanie Dumon, Giacomo Volpe, Carl Ward, Ruba Almaghrabi, Jidnyasa Gujar, Natasha Reeve, Manoj Raghavan, Martin R. Higgs, Grant S. Stewart, Eva Petermann, Paloma Garcia
Letter
Oncology
Ceri E. Oldreive, Philip J. Byrd, Grant S. Stewart, Alexander J. Taylor, Sana Farhat, Anna Skowronska, Edward Smith, Manoj Raghavan, Dragana Janic, Lidija Dokmanovic, Sam Clokie, Nicholas Davies, Marwan Kwok, Guy Pratt, Shankara Paneesha, Paul Moss, Tatjana Stankovic, Malcolm Taylor
LEUKEMIA & LYMPHOMA
(2019)
Article
Genetics & Heredity
Salam A. Assi, Maria Rosaria Imperato, Daniel J. L. Coleman, Anna Pickin, Sandeep Potluri, Anetta Ptasinska, Paulynn Suyin Chin, Helen Blair, Pierre Cauchy, Sally R. James, Joaquin Zacarias-Cabeza, L. Niall Gilding, Andrew Beggs, Sam Clokie, Justin C. Loke, Phil Jenkin, Ash Uddin, Ruud Delwel, Stephen J. Richards, Manoj Raghavan, Michael J. Griffiths, Olaf Heidenreich, Peter N. Cockerill, Constanze Bonifer
Article
Hematology
Dragana Milojkovic, Nicholas C. P. Cross, Sahra Ali, Jenny Byrne, Gavin Campbell, Fiona L. Dignan, Mark Drummond, Brian Huntly, Scott Marshall, Mary Frances McMullin, Pratap Neelakantan, Manoj Raghavan, Muttuswamy Sivakumaran, Jane Tighe, Farooq Wandroo, Fenella Willis, Fiona Glen, Louise Fildes, Sarah J. Collington, Jacqueline Ryan, Richard E. Clark, Adam J. Mead
Summary: The management of chronic myeloid leukaemia (CML) has evolved significantly, but real-world data shows discrepancies with ELN recommendations. Molecular assessments are often missed, some patients do not switch TKI despite treatment failure, and cardiovascular risk factors are not consistently considered during TKI management. Different TKIs have varying effects on achieving major and deep molecular responses, highlighting the need for improvement in caring for CML patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Sally B. Killick, Daniel H. Wiseman, Lynn Quek, Catherine Cargo, Dominic Culligan, Helen Enright, Simone Green, Wendy Ingram, Gail L. Jones, Jonathan Kell, Pramila Krishnamurthy, Austin Kulasekararaj, Juliet Mills, Ghulam Mufti, Elspeth M. Payne, Manoj Raghavan, Simon J. Stanworth, Alex Sternberg, David Bowen, British Society For Haematology
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Sally B. Killick, Wendy Ingram, Dominic Culligan, Helen Enright, Jonathan Kell, Elspeth M. Payne, Pramila Krishnamurthy, Austin Kulasekararaj, Manoj Raghavan, Simon J. Stanworth, Simone Green, Ghulam Mufti, Lynn Quek, Catherine Cargo, Gail L. Jones, Juliet Mills, Alex Sternberg, Daniel H. Wiseman, David Bowen
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Simone Claudiani, Jeroen J. W. M. Janssen, Jenny Byrne, Graeme Smith, Nicole Blijlevens, Manoj Raghavan, Matthew Smith, Richard E. Clark, Susan Mclain-Smith, Angela M. Carter, Dragana Milojkovic, Jane F. Apperley
Summary: Bosutinib has demonstrated good effectiveness and safety in treating patients with chronic myeloid leukemia, particularly in terms of improving cytogenetic and molecular response rates.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2022)
Review
Hematology
Sophie G. Kellaway, Daniel J. L. Coleman, Peter N. Cockerill, Manoj Raghavan, Constanze Bonifer
Summary: The transcription factor RUNX1 is crucial for hematopoietic development, and its mutations can lead to hematopoietic defects and cancer susceptibility. This review summarizes the literature on inherited and acquired RUNX1 mutations, focusing on mutations that alter the structure of the RUNX1 protein and discussing their impact on RUNX1 function. The study also summarizes the expression of mutant RUNX1 proteins in cells and explores the molecular mechanism by which these variants reprogram the epigenome, leading to malignancy in stem cells.
EXPERIMENTAL HEMATOLOGY
(2022)
Article
Hematology
Alexander Sternberg, Rebecca Boucher, Helen Chantal Coulthard, Manoj Raghavan, Dominic Culligan, Aimee Jackson, Catherine Cargo, Mike Dennis, Marlen Metzner, Jennifer O'Sullivan, Rachel Moore, David Bowen, Paresh Vyas
Summary: Combination therapy with eltrombopag and azacitidine showed promising efficacy and safety in treating high-risk myelodysplastic syndromes, although caution is needed due to potential adverse effects.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biology
Nuria Vilaplana-Lopera, Vincent Cuminetti, Ruba Almaghrabi, Grigorios Papatzikas, Ashok Kumar Rout, Mark Jeeves, Elena Gonzalez, Yara Alyahyawi, Alan Cunningham, Aysegul Erdem, Frank Schnutgen, Manoj Raghavan, Sandeep Potluri, Jean-Baptiste Cazier, Jan Jacob Schuringa, Michelle A. C. Reed, Lorena Arranz, Ulrich L. Guenther, Paloma Garcia
Summary: This study identifies a novel metabolic crosstalk between AML and stromal cells, where AML cells stimulate stromal cells to secrete acetate for their own consumption. Transcriptome analysis and metabolic NMR analysis show that stromal cells exhibit a higher rate of glycolysis when co-cultured with AML cells. It is also found that acetate in stromal cells is derived from pyruvate via chemical conversion under the influence of reactive oxygen species (ROS) transferred from AML cells via gap junctions.
Article
Oncology
Charles F. Craddock, Aimee E. Houlton, Lynn Swun Quek, Paul Ferguson, Emma Gbandi, Corran Roberts, Marlen Metzner, Natalia Garcia-Martin, Alison Kennedy, Angela Hamblin, Manoj Raghavan, Sandeep Nagra, Louise Dudley, Keith Wheatley, Mary Frances McMullin, Srinivas P. Pillai, Richard J. Kelly, Shamyla Siddique, Michael Dennis, Jamie D. Cavenagh, Paresh Vyas
CLINICAL CANCER RESEARCH
(2017)